$VIVS

Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10%

Esousa Group Holdings LLC and Michael Wachs together own 9.9% of VivoSim Labs (VIVS) common stock, or 319,429 shares, as of June 30, 2026. They hold warrants for 576,542 additional shares but cannot exercise them to exceed the 9.9% ownership limit. They have sole voting and dispositive power over the 319,429 shares.

Original reporting
Published Aug 18, 2026, 1:32 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$VIVS
Neutral
medium confidence
Mentioned
$VIVS
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VIVSNeutralLow
01

Why it matters

The main new information is the reported beneficial ownership level (9.9%) and that warrants are excluded from beneficial ownership due to a 9.9% beneficial ownership limitation.

02

Market read

This is a regulatory ownership update that may slightly affect perceived control dynamics but does not indicate a transaction, financing, or operational change.

03

What to watch

Traders may be over-weighting the stake size; the key constraint is the beneficial ownership limitation that prevents warrant exercises from pushing ownership above 9.9%.

Relevance 4/10Novelty 4/10Timing: today’s SEC filing update (amended Schedule 13G/A)

Background

The article summarizes an amended Schedule 13G/A for VivoSim Labs, detailing beneficial ownership and warrant terms.

Company-level read

Ticker impact

$VIVSNeutralMedium confidence
Context

VivoSim Labs filed an amended Schedule 13G showing Esousa Group Holdings LLC and Michael Wachs beneficially own 9.9% of shares, with warrants capped below that level.

Expected impact

Limited near-term impact; any reaction is likely modest unless investors interpret the stake as signaling control or future financing.

Evidence & confidence

This is a beneficial ownership disclosure (13G/A) with a stated 9.9% cap on warrant-driven ownership, which is typically incremental rather than a fundamental catalyst.

Market effects

Minimal, as the disclosure is company-specific and does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

The 9.9% cap may reduce the market’s control concerns, so the disclosure could be less bullish than a headline “near-10% stake” might imply.

Key entities

  • VivoSim Labs, Inc.

    Company whose amended Schedule 13G/A discloses Esousa and Michael Wachs’ beneficial ownership and warrant limitation.

  • Esousa Group Holdings LLC

    Reporting person with beneficial ownership of 319,429 shares (9.9%) and warrants subject to a 9.9% cap.

  • Michael Wachs

    Co-reporting person with beneficial ownership of 319,429 shares (9.9%) and warrants subject to a 9.9% cap.

Related articles

$VIVSMedAI 8/10

VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 – Minichart

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

$VIVSMed

VivoSim Labs, INC. (VIVS): Results of Operations and Financial Condition

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, t

$VIVSMed

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.

$VIVSMedAI 8/10

Why Is VivoSim Labs Stock Falling Thursday? - VivoSim Labs (NASDAQ:VIVS)

VivoSim Labs (NASDAQ:VIVS) said it signed a securities purchase agreement to sell 4.71 million shares and warrants to a healthcare-focused institutional investor at an effective $0.85 per share, raising about $4.0 million gross. New warrants are exercisable at $0.85 for five years, and the company plans to amend May 2024 warrants to lower the exercise price to $0.85 and extend terms, pending approval. Shares were down 26.52% to $0.62.